MedTrace Logo

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

NCT00542685 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 551

Last updated 2012-11-16

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

PD 0332334

Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.

DRUG

Placebo

Capsules, oral, placebo BID, 8 weeks with 2 week taper.

DRUG

PD 0332334

Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.

DRUG

PD 0332334

Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00542685 on ClinicalTrials.gov